Core Viewpoint - Descartes Systems (DSGX) has faced significant selling pressure, resulting in a 13.8% decline in stock price over the past four weeks, but analysts anticipate improved earnings in the near future [1] Group 1: Technical Analysis - The Relative Strength Index (RSI) is utilized to determine if a stock is oversold, with a reading below 30 indicating oversold conditions [2] - DSGX has an RSI reading of 24.09, suggesting that the heavy selling may be nearing exhaustion, potentially leading to a price rebound [5] Group 2: Fundamental Analysis - Analysts have raised earnings estimates for DSGX by 22.2% over the last 30 days, indicating a positive trend that typically correlates with price appreciation [7] - DSGX holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, further supporting the potential for a turnaround [8]

Core Viewpoint - nCino (NCNO) has experienced significant selling pressure, resulting in a 16.6% decline over the past four weeks, but analysts anticipate improved earnings in the near future [1] Group 1: Technical Indicators - The Relative Strength Index (RSI) is utilized to determine if a stock is oversold, with readings below 30 indicating oversold conditions [2] - The current RSI for NCNO is 28.38, suggesting that the heavy selling may be nearing exhaustion, indicating a potential rebound [5] Group 2: Fundamental Indicators - Analysts have raised earnings estimates for NCNO by 0.7% over the last 30 days, which typically correlates with price appreciation [7] - NCNO holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks, indicating strong potential for a turnaround [8]

Core Insights - Kimball Electronics, Inc. (KE) is set to report its second-quarter fiscal 2026 results on February 4, with sales expected to decline by 4.2% year-over-year to $342.5 million and earnings estimated at 28 cents per share, reflecting a 3.5% decrease from the previous year [1][9]. Group 1: Earnings Performance - Kimball Electronics has consistently surpassed the Zacks Consensus Estimate in the last four quarters, with an average surprise of 49.71% [2]. - The current Earnings ESP for Kimball Electronics is 0.00%, and it holds a Zacks Rank of 3 (Hold), indicating uncertainty regarding an earnings beat this time [7]. Group 2: Factors Influencing Q2 Results - The company's second-quarter results are expected to benefit from its expansion in the high-growth medical contract manufacturing sector, particularly with a new 300,000 sq. ft. facility in Indianapolis [3]. - Demand for medical devices is driven by an aging population, increased healthcare access, and advancements in connected drug-delivery systems, which are anticipated to positively impact Kimball Electronics' performance [4]. - Operational improvements, including reduced inventory and lower selling, general, and administrative expenses, along with significant debt reduction, are likely to enhance the bottom line for the quarter [5]. Group 3: Industry Challenges - Despite the positive factors, overall results may be negatively impacted by industry-wide softness in the automotive and industrial segments, which could outweigh the strong performance in the medical division [6]. - The company's heavy reliance on a few large medical and automotive customers presents an additional concern [6].

Company Performance - AAR's stock has increased by 28.8% over the past month and reached a new 52-week high of $108.36 [1] - Year-to-date, AAR has gained 28.8%, while the Zacks Aerospace sector and the Zacks Aerospace-Defense Equipment industry have seen gains of 39.6% and 46.6%, respectively [1] Earnings and Revenue Expectations - AAR has consistently beaten earnings estimates, with an EPS of $1.18 reported against a consensus estimate of $1.02 in the last earnings report [2] - For the current fiscal year, AAR is projected to earn $4.85 per share on revenues of $3.2 billion, reflecting a 24.04% increase in EPS and a 15.23% increase in revenues [3] - For the next fiscal year, expected earnings are $5.61 per share on revenues of $3.44 billion, indicating a year-over-year change of 15.67% in EPS and 7.42% in revenues [3] Valuation Metrics - AAR has a Value Score of C, a Growth Score of A, and a Momentum Score of C, resulting in a VGM Score of A [6] - The stock trades at 22 times the current fiscal year EPS estimates, below the peer industry average of 37.3 times [6] - On a trailing cash flow basis, AAR trades at 19.5 times, compared to the peer group's average of 33.9 times [6] Zacks Rank - AAR holds a Zacks Rank of 2 (Buy), supported by favorable earnings estimate revisions from analysts [7] - The recommendation is for investors to select stocks with a Zacks Rank of 1 (Strong Buy) or 2 (Buy) and Style Scores of A or B, indicating potential for further stock price appreciation [7] Industry Comparison - AAR's performance is strong, but Moog Inc. (MOG.A) is also a notable competitor with a Zacks Rank of 2 (Buy) and similar style scores [8] - Moog Inc. is expected to post earnings of $9.95 per share on revenues of $4.2 billion for the current fiscal year, having beaten consensus estimates by 14.29% last quarter [9] - The Aerospace - Defense Equipment industry is positioned in the top 26% of all industries, suggesting favorable conditions for both AAR and MOG.A [10]

Core Viewpoint - Bio-Techne Corporation (TECH) is expected to release its second-quarter fiscal 2026 results on February 4, with adjusted earnings per share (EPS) anticipated at 43 cents, reflecting a 2.4% increase from the previous year, while revenues are projected at $292 million, indicating a 1.7% decrease year-over-year [1][2]. Group 1: Earnings Performance - In the last reported quarter, Bio-Techne posted adjusted EPS of 42 cents, matching the Zacks Consensus Estimate, with the company beating earnings in three of the last four quarters and matching once, averaging a surprise of 6.58% [1]. - Estimates for earnings have remained constant at 43 cents over the past 30 days, indicating stability in expectations leading up to the announcement [3]. Group 2: Revenue Estimates - The Zacks Consensus Estimate for revenues is set at $292 million, which represents a decrease of 1.7% from the year-ago figure [2]. - The consensus estimate for the Spatial Biology segment's revenues is pegged at $81.6 million, down 3% from the previous year [15]. Group 3: Factors Influencing Performance - Ongoing macro uncertainties, including tariffs and potential NIH budget cuts, may add to customer uncertainty and temporarily slow growth momentum in the second quarter of fiscal 2026 [4]. - The timing related to cell therapy programs negatively impacted sales in the previous quarter, and this trend is expected to continue [5]. - The core portfolio of research-use-only proteomic agents, featuring over 6,000 proteins and 400,000 antibody types, is likely to support global customers in advancing therapeutics for precision diagnostics [6]. Group 4: Segment Developments - The protein analytical instrumentation business is expected to maintain strong momentum, with the ProteinSimple solution resuming double-digit growth [7]. - Demand for the next-generation high-throughput instrument, Leo, appears to be strong, contributing positively to quarterly results [8]. - Major developments include a licensing agreement with Monod Bio for exclusive rights to a subset of AI-designed bispecific binding proteins and a strategic distribution partnership with Sphere Bio for ultrasensitive immunoassays targeting Alzheimer's biomarkers [10]. Group 5: Challenges and Growth Areas - The Spatial Biology segment may face revenue declines due to the divestiture of the Exosome Diagnostics business, despite growth in the RNAscope product suite [12]. - The segment is likely to encounter headwinds from NIH funding uncertainties and a weaker biotech funding environment [13]. - The company has launched several new products and partnerships aimed at enhancing its offerings in spatial biology and diagnostics, which may contribute to top-line performance [14].

分组1 - ChoiceOne Financial Services, Inc. reported quarterly earnings of $0.92 per share, exceeding the Zacks Consensus Estimate of $0.91 per share, and up from $0.83 per share a year ago, representing an earnings surprise of +1.66% [1] - The company posted revenues of $42.94 million for the quarter ended December 2025, which missed the Zacks Consensus Estimate by 2.19%, compared to year-ago revenues of $24.34 million [2] - The stock has added about 0.1% since the beginning of the year, underperforming the S&P 500's gain of 1.8% [3] 分组2 - The current consensus EPS estimate for the coming quarter is $0.88 on revenues of $43.6 million, and for the current fiscal year, it is $3.52 on revenues of $176.7 million [7] - The Zacks Industry Rank for Financial - Miscellaneous Services is currently in the top 39% of over 250 Zacks industries, indicating a favorable outlook for the industry [8] - The estimate revisions trend for ChoiceOne Financial Services was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, suggesting it is expected to perform in line with the market [6]

分组1 - American Express reported quarterly earnings of $3.53 per share, slightly missing the Zacks Consensus Estimate of $3.54 per share, but showing an increase from $3.04 per share a year ago, resulting in an earnings surprise of -0.28% [1] - The company posted revenues of $18.98 billion for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 0.84% and increasing from $17.18 billion year-over-year [2] - Over the last four quarters, American Express has exceeded consensus EPS estimates three times and has also topped consensus revenue estimates three times [2] 分组2 - The stock has underperformed the market, losing about 3.1% since the beginning of the year, while the S&P 500 has gained 1.8% [3] - The current consensus EPS estimate for the upcoming quarter is $3.95 on revenues of $18.44 billion, and for the current fiscal year, it is $17.50 on revenues of $78.16 billion [7] - The Zacks Industry Rank for Financial - Miscellaneous Services is currently in the top 39% of over 250 Zacks industries, indicating a favorable outlook for the industry [8]

Core Insights - Archer Daniels Midland Company (ADM) is expected to report a decline in earnings for the fourth quarter of 2025, with an estimated earnings per share (EPS) of 83 cents, reflecting a 27.2% decrease from the previous year [1][2]. Financial Performance - The Zacks Consensus Estimate for ADM's revenues is projected at $22.3 billion, indicating a 3.8% growth compared to the same quarter last year [2]. - In the last reported quarter, ADM achieved an earnings surprise of 3.4%, beating the Zacks Consensus Estimate by an average of 4.3% over the last four quarters [3]. Segment Analysis - The Ag Services and Oilseeds segment is anticipated to face continued pressure due to challenging margins, with revenues estimated at $17.7 billion, suggesting a 4.9% year-over-year growth [4][7]. - The Carbohydrate Solutions segment is expected to report revenues of $2.6 billion, indicating a 4.9% decline year-over-year, driven by soft global demand for sweeteners and starches [6][7]. - The Nutrition segment is projected to be a positive contributor, with revenues estimated at $1.85 billion, reflecting a 4.3% year-over-year growth, supported by portfolio optimization and cost discipline [8][9]. Market Dynamics - The company is experiencing margin pressures in its Refined Products and Other segment due to uncertainties in biofuel and trade policies, which have negatively impacted biodiesel margins [5]. - Despite these challenges, ADM is focusing on productivity improvements and innovation, particularly in biosolutions, biotics, flavors, and health and wellness, which are seeing increased customer engagement [10][11]. Valuation Metrics - ADM has a forward 12-month price-to-earnings ratio of 15.76X, which is below its five-year high of 16.91X and above the industry average of 13.59X [15]. - The stock has risen 10.5% over the past three months, contrasting with a 14.8% decline in the industry [15].

分组1 - Church & Dwight reported quarterly earnings of $0.86 per share, exceeding the Zacks Consensus Estimate of $0.84 per share, and showing an increase from $0.77 per share a year ago, resulting in an earnings surprise of +2.77% [1] - The company achieved revenues of $1.64 billion for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 0.39%, and up from $1.58 billion year-over-year [2] - Church & Dwight has outperformed the S&P 500 with a share price increase of about 9.7% since the beginning of the year, compared to the S&P 500's gain of 1.8% [3] 分组2 - The current consensus EPS estimate for the upcoming quarter is $0.95 on revenues of $1.52 billion, and for the current fiscal year, it is $3.73 on revenues of $6.31 billion [7] - The Zacks Industry Rank indicates that the Consumer Products - Staples sector is in the bottom 32% of over 250 Zacks industries, suggesting potential underperformance compared to higher-ranked industries [8]

Core Viewpoint - Pfizer is expected to report its Q4 and full-year 2025 earnings on February 3, with consensus estimates of $16.93 billion in sales and $0.57 earnings per share (EPS) [1][7]. Earnings Estimates - The Zacks Consensus Estimate for Pfizer's Q4 sales is $16.93 billion and EPS is $0.57, with a decline in 2026 earnings estimates from $3.15 to $2.99 per share over the past 60 days [1][2]. - The earnings surprise history shows Pfizer has exceeded earnings expectations in the last four quarters, with an average surprise of 35.33% [2][3]. Segment Performance Expectations - Q4 growth is anticipated from oncology drugs and Vyndaqel, but offset by weaker COVID products and Prevnar [7]. - Sales of Vyndaqel, Eliquis, Padcev, and Lorbrena are expected to drive top-line growth, while Prevnar and Xeljanz sales have declined [8]. - The Zacks Consensus Estimate for Eliquis alliance revenues is $2.14 billion, and for Prevnar family vaccines is $1.65 billion [10][11]. - Revenues from Comirnaty are expected to decline due to narrower COVID-19 vaccine recommendations, with estimates of $2.0 billion for Comirnaty and $289 million for Paxlovid [12][13]. Oncology and Specialty Care Insights - Oncology sales are expected to be driven by Xtandi, Lorbrena, and Braftovi-Mektovi, while Ibrance sales may decline [14]. - The Zacks Consensus Estimate for Padcev is $527 million and for Ibrance is $1.03 billion [15]. - In Specialty Care, Vyndaqel sales are expected to remain strong at $1.66 billion, while Xeljanz and Enbrel sales may decline [16]. Financial Guidance and Acquisitions - Pfizer expects total revenues for 2026 to be between $59.5 billion and $62.5 billion, with adjusted EPS in the range of $2.80-$3.00 [17]. - A one-time R&D charge related to the acquisition of Metsera will impact Q4 EPS [18]. Stock Performance and Valuation - Pfizer's stock has declined 1.6% over the past year, compared to a 16.4% return for the industry [20]. - The stock trades at a forward P/E ratio of 8.84, lower than the industry average of 18.18 and its five-year mean of 10.25 [23]. Long-Term Outlook - Pfizer's dependence on COVID-related revenues has decreased, with non-COVID operational revenues improving [26]. - The company is focusing on rebuilding its pipeline through acquisitions, with significant investments in business development [28]. - However, challenges remain, including declining COVID product sales and upcoming patent expirations that could negatively impact revenues by approximately $1.5 billion in 2026 [29][30]. - Long-term investors may consider holding the stock as Pfizer aims for growth from its oncology and obesity pipeline starting in 2029 [33].